Covaxin Neutralises Double Mutant Strain In India: Research Body ICMR


Made-in-India COVID-19 vaccine, Covaxin, neutralises multiple variants of SARS-CoV-2 COVID-19 virus

New Delhi:

Made-in-India COVID-19 vaccine, Covaxin, neutralises multiple variants of SARS-CoV-2 and effectively works against the double mutant strain as well, the Indian Council of Medical Research (ICMR) said today.

Bharat Biotech’s Covaxin has received Emergency Use Authorizations (EUAs) for COVID-19 treatment in India and in several countries across the world with another 60 in the process.

“ICMR study shows Covaxin neutralises against multiple variants of SARS-CoV-2 and effectively neutralises the double mutant strain as well,” the ICMR tweeted.

ICMR-National Institute of Virology has successfully isolated and cultured multiple variants of concern of SARS-CoV-2 virus: B.1.1.7 (the UK variant), B.1.1.28 (Brazil variant ) and B.1.351 (South Africa variant).

ICMR-NIV has demonstrated the neutralisation potential of Covaxin against the UK variant and Brazil variant, the top health research body said.

ICMR-NIV recently has been successful in isolating and culturing the double mutant strain B.1.617 SARS-CoV-2 identified in certain regions of India and several other countries, the ICMR stated.

“Covaxin has been found to effectively neutralise the double mutant strain as well,” it said.
 

(Except for the headline, this story has not been edited by NDTV staff and is published from a syndicated feed.)

.



Source link

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.